Date: 2013-12-02
Type of information: Distribution agreement
Compound: ConfirmMDx for Prostate Cancer
Company: MDxHealth (Belgium) Fortified Provider Network (USA)
Therapeutic area: Cancer - Oncology
Type agreement:
Action mechanism: ConfirmMDx for Prostate Cancer is an epigenetic assay to help distinguish patients who have a true-negative biopsy from those at risk for occult cancer. The test helps urologists rule out prostate cancer-free men from undergoing unnecessary repeat biopsies and, helps rule in high risk patients who may require repeat biopsies and potential treatment. The test is able to detect an epigenetic field effect or \"halo\" associated with the cancerization process at the DNA level in cells adjacent to cancer foci. This molecular \"halo\" around a cancer lesion can be present despite having a normal appearance under the microscope.
Disease: prostate cancer
Details: * On December 2, 2013, MDxHealth, a Belgian molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, has announced that it has signed agreement with Fortified Provider Network to provide their members access to the ConfirmMDx® for Prostate Cancer test. Fortified Provider Network (\"FPN\") is a national direct-contracted preferred provider network. FPN\'s select provider network is utilized by self-funded employer groups, insurance carriers and regional and local provider networks that process end-user patient claims. FPN offers the utilization of its network to its more than 200 payor clients and members who, in turn, are able to capitalize on the discounted fee schedules FPN has negotiated with its healthcare providers. FPN contracts with physicians, hospitals, ancillary facilities, mid-level providers and other specialty healthcare providers who have the option of participating in one or more of our products (group health, workers compensation or auto liability).
Financial terms:
Latest news:
